Pfizer acquires option to licence potential treatment for Parkinson’s Pfizer today announced an agreement with MedGenesis granting them an exclusive worldwide option to license a protein called glial cell line-derived neurotrophic factor (GDNF) and convection enhanced delivery (CED) technology. The Cure Parkinson’s Trust is delighted to report that today, MedGenesis announced this option agreement with Pfizer. This is very encouraging and should secure the necessary support for GDNF and CED if they are to be taken through the next stages of development. Currently there is a trial on-going in Bristol Southmead Hospital that is being co-funded by CPT and Parkinson’s UK. Sam Hatfield, CEO of The Cure Parkinson’s Trust commented, “The results of the GDNF trial in Bristol will not be released until well into 2016. Nevertheless, the promise of GDNF as an effective treatment for Parkinson’s has been an emotive subject for those living with the condition since 2003 when 5 people with Parkinson’s received the drug which hinted at the potential of this treatment.” He went on to say “for those who have followed this story from the outset, this latest agreement between Pfizer and MedGenesis at last provides some assurances that the onward development of GDNF and its method of delivery has the financial backing it will require if it is to become a genuine treatment option for people with Parkinson’s.”Please click here to read Parkinson's UK's press release.